In addition, activating point mutations of JAK2 coexisted with IKZF1 deletion in pediatric BCP-ALL with a BCR-ABL-like gene expression signature and a very poor outcome [18]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.